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Between April 2007 and November 2010, we treated 21 cases of hormone-refractory prostate cancer
with docetaxel-based chemotherapy. The administered dose of docetaxel was from 40 to 75 mg/m2, and
the treatments were repeated every 3 to 4 weeks. The patients were from 61 to 88 years old (median 78).
Fourteen patients were alive, and seven had died. According to the prostate specific antigen response, the
complete response rate was 30%, partial response was 10%, no change was 25%, and progressive disease was
25%, respectively. Median time to progression was 7.0 months (from 1 to 43 months), and median overall
survival time after chemotherapy was 11.5 months (from 3 to 44 months). One patient died of adverse
events. However, in most cases, hematological toxicities were tolerable and manageable, although
neutropenia of grade 3 to 4 was observed. On the other hand, non-hematological toxicities that led to
discontinuation of the therapy were observed in a few cases. Docetaxel-based chemotherapy was feasible
and effective even for patients over 80 years old. In responding cases, it is important to maintain the
chemotherapy as long as possible, by modifying the treatment procedures, while paying attention to the
adverse events.
(Hinyokika Kiyo 57 : 481-486, 2011)





























は，prostate specific antigen (PSA) 奏功率によって判定
した．有害事象は，common terminology criteria for
adverse events (CTCAE) v 3.0 を基準とした．
PSA 奏功率については，complete response (CR)
(PSA 値が基準値以内に低下），partial response (PR)
（50％以上の PSA 低下が 4週間以上持続），no change
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(NC) (PR と PD の中間），progressive disease (PD)
（25％以上の PSA 上昇，または新規病変の出現）に分
類した．また，DOC 療法開始時から PSA progression
までの期間 (time to progression ; TTP) および DOC 療






中央値78歳），治療時 PSA は 5.97∼266.43 ng/ml（平
均 59.44 ng/ml，中央値 35.60 ng/ml) であった．前治








量が 9例，投与期間の延長が 6例にみられた (Table
2）．
Table 1. Patients’ characteristics




Stage GS Bone Soft tissue
1 61 0 7.53 C 5＋5 RP, MAB ＋ −
2 66 0 11.3 B1 5＋3 RP, MAB, UFT − LN, local
3 67 0 5.8 D1 4＋4 MAB ＋
4 70 0 10.2 B1 4＋4 RP, MAB, EMP − Local
5 73 0 32.9 B1 4＋3 RP, LHRH→Castration ＋ LN
6 74 0 36.18 D2 5＋5 RTx, MAB ＋ −
7 75 0 11.5 B1 3＋4 RP, MAB, steroids, EMP, UFT, ZA ＋ −
8 76 0 38.6 C 4＋3 MAB, EMP, ZA ＋ −
9 76 0 164 D2 5＋4 MAB, steroids, UFT, ZA ＋ LN
10 78 1 49.6 B1 3＋5 RTx, MAB, EMP, steroids, ETP ＋ −
11 78 1 701.62 D2 5＋4 MAB, EMP − LN
12 80 1 2,981.75 D2 5＋5 MAB, ZA ＋ −
13 81 2 195.5 D1 5＋5 RP, MAB, EMP, steroids ＋ Lung
14 81 0 118 D2 5＋4 Castration, anti-androgen, EMP, steroids ＋ LN
15 83 1 211.8 D2 5＋5 MAB, EMP, ZA ＋ LN
16 83 1 3.7 C 3＋4 MAB, Castration, EMP − −
17 84 1 365.25 D2 4＋5 MAB, steroids ＋ −
18 85 3 887.62 D2 4＋5 MAB, EMP ＋ −
19 85 2 298.5 D1 5＋3 MAB, EMP, steroids, ZA ＋ LN
20 85 1 202 D2 5＋5 MAB, EMP, steroids ＋ LN
21 88 2 11.98 D1 5＋5 MAB, steroids − LN
PS : ECOG (Eastern Cooperative Oncology Group) performance status, GS : Gleason score at biopsy, MAB : maximum androgen
blockade, RP : radical prostatectomy, EMP : estramustine phosphate, ZA : zoledronic acid, RTx : radiation therapy, UFT : tegafur-uracil,




治療効果は，20例中，CR が 6例，PR が 2例，NC









あった (Fig. 2A）．DOC 療法開始後の OS は，中央値






中の11例はすべて PR または NC 例であり， 3 ∼23
コース（平均12.5コース）施行している．治療継続例
のドセタキセルの投与量は，減量例を含めると，最終
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1 70→60 3→4 3 DEX, BET, EMP CR 14 8 Alive*
2 75→60 3→4 16 DEX, EMP, ZA, LH-RH NC 65 23 Alive*
3 75 3 11 BET, PSL, EMP, ZA, LH-RH PR 28 15 Dead
4 75→70 4 6 DEX, BET, EMP PD 77 12 Alive
5 60→40 4 12 DEX, BET, EMP, ZA NC 102 11 Alive*
6 70→60→50 3 5 DEX, ZA CR 10 3 Alive*
7 60→70→60 4 16 PSL, ZA, LH-RH CR 121 23 Alive*
8 60 4→6 19 DEX, EMP, ZA CR 51 20 Alive*
9 75→60→40 3→4 18 BET, ZA, LH-RH CR 68 17 Alive*
10 50 4 3 DEX, ZA PR 109 14 Dead
11 60 3→4 5 BET, LH-RH NC 19 11 Dead
12 70→40 4 14 DEX, ZA, LH-RH CR 21 14 Alive*
13 60 3→4 23 DEX, ZA NC 129 44 Alive*
14 60→50→60 4 12 DEX, ZA NC 63 11 Alive*
15 40 4 8 BET, ZA PD 11 15 Dead
16 60→40 4 5 BET NC 85 5 Alive*
17 60 4 3 ZA, LH-RH PD 21 3 Alive
18 60 N/A 1 DEX, LH-RH N/A 18 N/A Dead**
19 40 4 2 DEX, ZA, LH-RH PD 23 5 Dead
20 40 4 7 DEX, ZA NC 7 6 Alive*
21 60→40 4 3 DEX, EMP, ZA, LH-RH PD 8 5 Dead
DOC : docetaxel, DEX : dexamethazone, EMP : estramustine phosphate, ZA : zoledronic acid, LH-RH : leutenizing hormone-releasing
hormone analogue, BET : betamethazone, PSL : prednizolone, RTx : radiation therapy, PD : progressive disease, NC ; no change, PR :
partial response, N/A : no account. * DOC therapy has been continued. ** The patient was died of chemotherapeutic adverse
events. † Duration between the initial diagnosis and the start of DOC therapy. †† Survival time after start of DOC therapy.
的にはすべて 40∼60 mg/m2 であった (Table 2）．
有害事象についてみると， 1例に治療関連死を認め
た（ 1コース目で有熱性好中球減少症，敗血症，DIC


























m2 の 3 週間ごと投与か DOC 30 mg/m2 の毎週投与
（ 5回連続投与， 1週休薬）である1,2)．一方，本邦に
おいても投与法の検討が行われ，ステロイド併用，
DOC 30 mg/m2 の 3 週連続投与（ 1 週休薬）または















Fig. 1. Time dependent change of serum prostate specific antigen (PSA) in each patient. The value of PSA at
initiation of the chemotherapy was regarded as 100％. A : For cases of complete response (CR) and
partial response (PR), B : For cases of no change (NC), C : For cases of progressive disease (PD).
ている．他にも予後不良因子として，痛みの有無，骨
以外の臓器転移の有無，化学療法開始前の PSA-
doubling time (PSA-DT) などが報告されている13~15)．
しかし，治療効果に年齢による差はないとの報告が多
い16,17)．また，治療スケジュールについてみると，
Italiano らは， 3週ごとの投与よりも， 1∼ 2週の休
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Fig. 2. Kaplan-Meier curve for the time to progression (TTP) of PSA (A), and for the overall survival (OS) time
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